NeoDynamics Receives First US Order from Top University Hospital
NeoDynamics reaches important milestone in the US with the receipt of its first commercial order for NeoNavia ®
NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced the initiation of their first NeoNavia® order from a prominent US university hospital specializing in the treatment of breast cancer. However modest in size, the order will serve as an important reference as the commercial rollout continues to garner interest and acceptance at both academic and community based breast centers throughout the U.S. This milestone further demonstrates the commercial viability of the innovative pulse technology, and its role in shifting the paradigm in the diagnosis of breast cancer, which is in line with what has been communicated. The company commercially launched NeoNavia® in the US at two prestigious conferences in the 2nd quarter of 2023.
“We are very pleased that our go-to-market strategy in the US is starting to yield results. Our objective is to work with leading university hospitals to gain acceptance from key opinion leaders and experts within the field of diagnosis and treatment of breast cancer.” says Anna Eriksrud, CEO.
NeoNavia ® is a minimally invasive biopsy system designed to provide controlled needle insertion, accurate lesion targeting, and high tissue yield in technically difficult lesions in the breast and axillary lymph nodes.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
Matt Colpoys, CEO NeoDynamics Inc., phone +1 716 536 2971 or e-mail matt.colpoys@neodynamics.com
About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institute in Sweden.. NeoDynamics’ shares are listed on Nasdaq First North Growth Market Stockholm: NEOD.ST. The company’s Certified Adviser is Redeye AB.
About NeoNavia®
NeoNavia® is the first vacuum-assisted device utilizing pulse technology for high yield, low risk, targeted biopsies in the breast and axillary lymph nodes. The innovative platform provides 3 needle options designed for accurate lesion targeting and greater tissue sampling with minimal trauma to surrounding tissue.
About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.
Attachments
Final data set from NeoDynamics’ PULSE study presented at The SBI Breast Imaging Symposium
